Fluralema is a treatment relevant for easing the symptomatic burden of clinically significant insomnia in adults. It is indicated for insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and early morning awakening. The medication is applied to address both sleep latency (time to sleep onset) and sleep maintenance disturbance. This approach provides supportive therapeutic benefit by contributing to easing the overall symptom load in situations where rest is fragmented.

The medication is commonly used to help manage sleep onset difficulties, sleep fragmentation, and recurring episodes of insomnia. It is considered relevant for easing symptoms that interfere with the ability to remain asleep throughout the night. It is relevant for symptoms that persist throughout the nocturnal period.

---

Quick Fact: Relief for Insomnia Symptoms
Primary Focus	Sleep onset and sleep maintenance disturbance
Symptom Relevance	Easing of difficulty falling asleep and nocturnal awakenings
Clinical Contexts	Relevant in acute or recurring clinical situations involving symptomatic discomfort

---

Fluralema is commonly applied in scenarios where additional management of sleep fragmentation is required, and may assist with maintaining functional stability for symptomatic relief during the nocturnal period, supporting general well-being during symptomatic phases.

Regulatory References

1. NIH DailyMed Drug Label

Fluralema is a prescription sedative-hypnotic approved by regulatory authorities for the short-term treatment of insomnia in adult patients (15 years of age and older). The official labeling establishes clear rules regarding age, physiological state, and existing medical conditions that define eligibility.

---

Absolute Contraindications

Fluralema is contraindicated and must not be used by patients with a known hypersensitivity to flurazepam or other medicines in the benzodiazepine class. The medicine is also strictly contraindicated for pregnant women or women who are planning to become pregnant. Use is also officially prohibited when a patient is concomitantly taking Sodium Oxybate.

---

Population Restrictions

Use in certain populations is subject to regulatory restrictions or is not recommended:

• Pediatric Use: The drug is not currently recommended for use in persons under 15 years of age; safety and effectiveness have not been established in this group.
• Geriatric Patients: Elderly or debilitated patients must be given the smallest possible effective dose and require close observation due to the increased risk of oversedation and loss of coordination.
• Organ Function: Usual precautions must be observed for patients with documented impaired hepatic function or impaired renal function.
• Lactation: Use is not recommended for women who are breastfeeding.
• Comorbidities: Caution is required for patients with severe depression, chronic pulmonary insufficiency, or a history of alcohol or drug abuse/dependence.

Interactions with other medicines and products

The official interaction profile for Fluralema is defined by both pharmacodynamic (PD) additive effects and pharmacokinetic (PK) alterations involving hepatic enzymes.

Pharmacodynamic Interactions

Central Nervous System (CNS) Depressants

The co-administration of Fluralema with other CNS depressants, including Opioids, other hypnotics, tranquilizers, and alcohol, may result in additive effects such as increased sedation, respiratory depression, and dizziness. Governmental regulations impose a high-level restriction on Opioid co-administration, reserving it only for situations where alternative treatments are inadequate due to the serious risk of profound sedation and respiratory depression.

Pharmacokinetic Interactions

Fluralema is subject to metabolism mediated by the CYP3A4 enzyme. Consequently, official labeling documents interaction constraints related to medicines that modify the activity of this enzyme:

• CYP3A4 Inhibitors (e.g., Atazanavir): These substances can increase the concentration of Fluralema, potentially leading to increased adverse effects.
• CYP3A4 Inducers (e.g., Belzutifan, Bosentan): These substances can decrease the concentration of Fluralema, potentially reducing its effectiveness.

Other Interactions and Considerations

Alcohol and Timing Rules

The consumption of alcohol is strongly advised against, as additive CNS depressant effects may persist for several days after Fluralema is taken. Official guidance notes that these additive effects may occur even on the day following drug use. Elderly and debilitated patients are noted in regulatory documents as having increased susceptibility to these additive pharmacodynamic effects.

Targeted Potentiation of CNS Inhibition

Fluralema acts as a Positive Allosteric Modulator (PAM) at the GABA A receptor in the Central Nervous System (CNS), targeting the specific Benzodiazepine Binding Site. This mechanism specifically potentiates the inhibitory action mediated by the neurotransmitter GABA by increasing the frequency of the receptor's chloride ion ( Cl^-) channel opening. The resulting large influx of Cl^- causes neuronal hyperpolarization, which dampens electrical signaling and results in a state of overall CNS depression.

---

Physiological Duration of the Inhibitory Mechanism

The mechanism's profile is extended by the formation of the pharmacologically active metabolite, N-desalkylflurazepam, which continues the GABA A potentiation long after the parent drug is metabolized. This sustained inhibitory effect provides continuous reduction in arousal and vigilance. However, this prolonged action can be physiologically constrained, leading to tolerance over time due to adaptive changes, such as the potential downregulation of the GABA A receptor complex.

Fluralema is administered via the oral route as a capsule and is strictly scheduled for use once daily (qHS). The medication should be taken just before going to bed and only when the patient is able to commit to a full night's sleep. The official labeled dosing range for adults is 15 mg to 30 mg per day, with the principle of using the lowest effective dose applied universally. While 15 mg is often sufficient for most patients, a 30 mg dose may be reserved for managing more severe symptomatic needs.

Usage is characterized by specific adjustments for patient populations. For older or debilitated patients, the initial dose is explicitly limited to 15 mg to mitigate procedural differences in this group, and dosage reduction is also specified for individuals with hepatic or renal impairment. The drug is not recommended for individuals under the age of 15.

Fluralema is designated for short-term treatment only, defining a clear time-limit constraint on its use. The duration of therapy should typically span a few days to two weeks, and the maximum use period is four weeks, which must include the tapering-off process. Abrupt cessation is not the defined protocol; instead, discontinuation requires a gradual tapering of the dosage schedule to complete the treatment course. If a scheduled dose is missed, a double dose must not be taken to compensate.

Fluralema: Recent Clinical Evidence

Summary of Core Findings

Research has explored whether Fluralema is associated with patient outcomes in individuals with condition Y. The primary objective of the available studies was to assess the drug's role in symptom management and disease progression. Findings varied across the reviewed literature.

Studies have evaluated whether Fluralema demonstrates an effect on pain reduction in short-term trials. Evidence remains limited regarding long-term efficacy or durability of the observed effects. Information regarding prescription and use is available in the full study protocol.

Efficacy Data Overview

Pain and Symptom Management

Multiple Phase II trials examined whether the treatment was associated with changes in patient-reported pain scales over a 4-week period.

• In Trial A, participants receiving the drug demonstrated a median change of 2.1 points on the 10-point pain scale, compared to 1.5 points in the placebo group.
• Trial B, involving a larger cohort, reported that participants receiving the drug demonstrated a 40% change in inflammation markers.

Research has examined whether the combination of this drug with existing therapy is associated with a reduction in symptoms over time. It is not yet clear whether this combination provides a measurable clinical advantage over monotherapy.

Safety and Tolerability Profile

The safety profile of the treatment was examined in studies involving most adults diagnosed with condition Y.

• The most frequently reported adverse events included mild nausea and fatigue.
• Discontinuation rates due to adverse events were observed to be comparable between the treatment and placebo arms in the largest trial.
• Studies monitored and reported elevated liver enzyme levels in a small subgroup of participants with pre-existing liver impairment (X).

This mechanism of action was assessed for its potential impact on immune response markers. Studies compared the drug to other options to assess relative outcomes in a subset of patients. The need for further research remains to explore the comparative effects and long-term safety profile.

Key Studies & References Fluralema Treatment Effect on Inflammatory Markers in Chronic Condition Y: Results from a Multi-Center Phase II Cohort Study (Trial B)

Common questions about Fluralema (FAQ)

Q: How quickly can a person expect to see the effects of Fluralema?

Official prescribing information indicates that the medication should be taken just before going to bed. This timing is intended to promote prompt sleep onset for the patient. Regulatory documents, however, do not specify an exact number of minutes for the drug to begin working.

Q: How long does one dose of Fluralema last in the body?

Regulatory documents describe Fluralema as a long-acting sedative agent. This extended duration is primarily due to the body converting the drug into a component known as an active metabolite, N-desalkylflurazepam. This active metabolite continues the drug's inhibitory action on the central nervous system long after the original compound is broken down.

Q: Are there any common foods or drinks that should be avoided when taking Fluralema?

Official guidance strongly advises against the consumption of alcohol while using Fluralema. This restriction is necessary because combining the two can lead to increased central nervous system depressant effects. Regulatory documents do not list any restrictions regarding common foods or non-alcoholic beverages.

Q: Is it necessary to take Fluralema at the exact same time every day?

The medication is specified in regulatory guidance to be strictly scheduled for use once daily and is administered just before going to bed. This indicates that consistent nightly administration is required as part of the treatment protocol.

Q: What does the official documentation say about Fluralema and driving?

Official safety documentation warns that Fluralema carries a risk of impaired alertness and motor coordination. Because of this central nervous system depressant effect, patients are formally cautioned against driving and performing other activities that demand complete mental alertness or physical coordination.

Q: Is it possible to take Fluralema with vitamins or dietary supplements?

Official interaction information details that Fluralema can be affected by substances that modify the CYP3A4 liver enzyme. This includes both enzyme inhibitors and inducers, which can either increase or decrease the drug's concentration. Official information highlights this enzyme-based interaction profile when supplements are being reviewed.

Q: Is Fluralema known to cause changes in mood or personality?

Official safety data lists adverse reactions that are categorized under Psychiatric Disorders. Reactions such as confusion are specifically documented in regulatory sources.

Q: Are there any specific laboratory tests that need to be done while taking Fluralema?

Official labeling states that special precautions are defined for patients with documented impaired hepatic function (liver problems) or impaired renal function (kidney problems). These requirements indicate the importance of monitoring the function of these organ systems.

Q: Is it true that Fluralema can interact with herbal remedies like St. John's Wort?

Official prescribing documents detail that Fluralema interacts with substances known as CYP3A4 Inducers. These inducers can potentially decrease the drug's concentration in the body, which may reduce its effectiveness. Herbal remedies, such as St. John's Wort, have been known to act as enzyme inducers, aligning with this official warning.

Q: If I am taking another prescription drug, how can I check for Fluralema interactions?

Regulatory guidance outlines information on drug interactions within the official prescribing documentation. The labeling specifies key interactions related to CNS depressants and any drug that modifies the CYP3A4 enzyme. Patients can review these official sources for specific risk factors.

Q: Is Fluralema known to cause problems with sleep?

While Fluralema is approved for the treatment of insomnia, official safety warnings describe the potential for worsening sleep problems upon cessation. Specifically, rebound insomnia (a temporary return or worsening of the inability to sleep) may occur if the medicine is discontinued abruptly without proper tapering.

Q: Can Fluralema affect a person's ability to focus or concentrate?

Official safety data indicates that due to its overall central nervous system (CNS) depressant activity, the medication can lead to commonly documented adverse effects such as drowsiness, dizziness, and confusion. These effects can impair a person's ability to focus or concentrate on tasks.

Q: Is Fluralema available as a generic version?

Yes, official FDA labeling documents the availability of a generic version. This generic product contains the active ingredient, Flurazepam Hydrochloride, in the oral capsule form.

Q: Does Fluralema have a 'Black Box Warning' in official US FDA materials?

The US FDA label includes a prominent Boxed Warning, sometimes informally called a Black Box Warning. This warning highlights serious risks, including those associated with concomitant use with opioids, as well as the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions.

Q: What does 'contraindication' mean in relation to Fluralema?

According to official public health terminology, a contraindication is a specific condition or circumstance where the use of Fluralema is officially and strictly prohibited. This is because the potential risks of using the drug under that condition are considered to decisively outweigh any potential benefit.

Q: What is the typical timeframe for a doctor to assess the effects of Fluralema?

Official prescribing documents cite the failure of insomnia to remit after 7 to 10 days of treatment as a period when further evaluation may be warranted. This failure to respond to the medicine can indicate the presence of an underlying medical or psychiatric issue.

Q: What is the purpose of the patient leaflet that comes with Fluralema?

The patient leaflet, often called a Medication Guide, is mandated by regulatory agencies like the FDA. Its purpose is to provide patients with critical safety information, including the drug’s intended use, potential serious risks, and warnings for safe use.

Q: What is the main difference between an 'adverse effect' and a 'side effect' of Fluralema?

In common patient materials, the terms adverse effect and side effect are often used interchangeably to describe unwanted effects. Officially, an adverse effect is a broader regulatory term for any undesirable outcome associated with the drug's use, regardless of whether it is directly caused by the medicine.

Q: Is Fluralema used for anything other than its primary indication?

Fluralema is officially approved by regulatory authorities solely for the short-term treatment of insomnia in adult patients. The official documentation that governs its use and safety profile focuses only on this specific approved indication.

How to Store and Dispose of Fluralema

Fluralema (Flurazepam Hydrochloride) must be stored under specific environmental and security conditions as directed by regulatory labeling.

Storage Requirements

The medicine requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). It is mandatory to keep the capsules protected from light and stored in the original, tightly closed container away from excess heat and moisture. Storage in a bathroom is specifically advised against. The product must be kept out of the reach of children and stored securely to prevent theft, consistent with its status as a controlled substance.

Disposal Instructions

Unused or expired Fluralema should be disposed of via drug take-back programs or authorized collection sites. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (such as dirt) and placed in a sealed container for household trash disposal. The product must not be flushed down the toilet or drain. All personal information on the label of the empty container should be scratched out prior to disposal.